The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer

Ni, Xiao‐Guang; Bai, Xiaofeng; Mao, Yilei; Shao, Yongfu; Wu, Jianxiong; Shan, Yi; Wang, C.F.; Wang, J.; Tian, Yantao; Liu, Q.; Xu, Dong; Zhao, Ping

doi:10.1016/j.ejso.2004.09.007

Cited by 258 publications

(191 citation statements)

References 8 publications

Supporting

Mentioning

169

Contrasting

Unclassified

Order By: Relevance

“…This phenomenon is called the 'CEA surge,' and these initial increases in tumor marker levels during chemotherapy can confuse clinicians with resultant errors in the determination of benefits from the chemotherapy. In the case of CA19-9, it has been generally considered as an important marker for response to treatment, as well as for prognosis in pancreatic cancer [19]. However, although guidelines of the American Society of Clinical Oncology (ASCO) allow the use of CA19-9 during active treatment period for metastatic pancreatic cancer [20], data supporting routine CA19-9 measurements during chemotherapy for monitoring the clinical courses of patients with metastatic pancreatic cancer are not solid.…”

mentioning

confidence: 99%

Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer

et al. 2009

View full text Add to dashboard Cite

mentioning

confidence: 99%

Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer

et al. 2009

View full text Add to dashboard Cite

“…It is mainly secreted by digestive glandular cancers and their metastases. It is one of the most widely used markers for colorectal cancer, and has also been suggested as a marker for pancreatic cancer (11).…”

Section: Introductionmentioning

confidence: 99%

TPS, CA 19-9, VEGF-A, and CEA as Diagnostic and Prognostic Factors in Patients with Mass Lesions in the Pancreatic Head

Sandblom

Granroth

Rasmussen

2008

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

Introduction: Although numerous tumour markers are available for periampullary tumours, including pancreatic cancer, their specificity and sensitivity have been questioned. Materials and methods:To assess the diagnostic and prognostic values of tissue polypeptide specific antigen (TPS), carbohydrate antigen 19-9 (CA 19-9), vascular endothelial growth factor (VEGF-A), and carcinoembryonic antigen (CEA) we took serum samples in 56 patients with mass lesions in the pancreatic head. Among these patients, further investigations revealed pancreatic cancer in 20 patients, other malignant diseases in 12 and benign conditions in 24.Results: Median CEA in all patients was 3.4 μg/L (range 0.5-585.0), median CA 19-9 was105 kU/L (range 0.6-1 300 00), median TPS 123.5 U/L (range 15.0-3350) and median VEGF-A 132.5 ng/L (range 60.0-4317). Area under the curve was 0.747, standard error (standard error [SE] =0.075) for CEA, 0.716 (SE=0.078) for CA 19-9 and 0.822 (SE=0.086) for TPS in ROC plots based on the ability of the tumours to distinguish between benign and malignant conditions. None of the markers significantly predicted survival in the subgroup of patients with pancreatic cancer. Discussion: Our study shows that the markers may be used as fairly reliable diagnostic tools, but cannot be used to predict survival.

show abstract

“…CEA, CA19-9 and DUPAN-2 are recognized markers for PC (29,30). Ni et al (29) reported that the sensitivity of CA19-9 alone was 80%, and that the specificity of CEA combined with CA19-9 was 84% in the diagnosis of PC.…”

Section: Discussionmentioning

confidence: 99%

“…Ni et al (29) reported that the sensitivity of CA19-9 alone was 80%, and that the specificity of CEA combined with CA19-9 was 84% in the diagnosis of PC. Furthermore, the median survival time of patients with a CA19-9 serum level ≥1,000 U/ml was 6 months (29).…”

Section: Discussionmentioning

confidence: 99%

Temporomandibular dislocation caused by pancreatic cancer metastasis: A case report

et al. 2017

View full text Add to dashboard Cite

Abstract. Metastasis-induced dislocation of the temporomandibular joint (TMJ) is rare. The present study describes a case of TMJ dislocation caused by metastasis from pancreatic cancer, and discusses this in the context of literature on occlusal abnormality and/or dislocation due to metastasis. In the present case, unilateral TMJ dislocation was suspected when the patient first presented; destructive bone changes were not observed on conventional radiographs, and magnetic resonance imaging (MRI) revealed a tumorous lesion. The present case suggests that healthcare professionals should consider whether a malignant disease is present in cases of occlusal abnormality and/or dislocation of the TMJ, and that, in patients with TMJ dislocation that cannot easily be repositioned, additional imaging examinations, including MRI, should be performed as soon as possible, regardless of whether destructive bone changes are present. Metastasis to the TMJ is typically associated with generalized skeletal metastasis in the final stage of malignancy. Therefore, it is crucial to consider the possibility of cervical spine metastasis in order to decrease the risk of cervical fracture when attempting reduction of a TMJ dislocation, particularly in patients with a history of cancer.

show abstract

The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer

Cited by 258 publications

References 8 publications

Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer

Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer

TPS, CA 19-9, VEGF-A, and CEA as Diagnostic and Prognostic Factors in Patients with Mass Lesions in the Pancreatic Head

Temporomandibular dislocation caused by pancreatic cancer metastasis: A case report

Contact Info

Product

Resources

About